- Home
- HSTM vs ATXS Comparison
HSTM vs ATXS Comparison
Compare HSTM & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSTM | ATXS |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.2M | 722.1M |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | HSTM | ATXS |
|---|---|---|
| Price | $24.38 | $12.97 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 6 |
| Target Price | ★ $28.00 | $24.33 |
| AVG Volume (30 Days) | 194.7K | ★ 1.3M |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | ★ 4.75 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $298,590,000.00 | $706,000.00 |
| Revenue This Year | $5.13 | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | $35.55 | ★ N/A |
| Revenue Growth | ★ 3.68 | N/A |
| 52 Week Low | $23.77 | $3.56 |
| 52 Week High | $34.24 | $13.29 |
Technical Indicators
Market Signals| Indicator | HSTM | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 65.69 |
| Support Level | $23.77 | $12.70 |
| Resistance Level | $25.55 | $13.29 |
| Average True Range (ATR) | 0.59 | 0.22 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 28.64 | 67.84 |
Price Performance
Historical ComparisonAbout HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.